Key Highlights
- 0.37 is the negative consensus EPS estimate per the screener snapshot for Vistagen Therapeutics, Inc. (NASDAQ:VTGN), which is due to report fiscal second quarter 2027 results before the market opens on November 13, 2026.
- 0.30 is the USD loss per share for the fiscal quarter ended June 30, 2026, on a net loss of USD 13.0 million, versus USD 0.47 per share and USD 15.1 million a year earlier.
- 31.7 million is the USD total of cash, equivalents and marketable securities at June 30, 2026, versus USD 30.8 million of cash alone at March 31, 2026, per the company release.
- 8.33 million is the USD market Capitalization per the screener snapshot, a nano-cap level and well below the reported cash and securities, while 44,381,433 common shares were issued at June 30, 2026.
What Investors Expect From Vistagen Therapeutics, Inc. (NASDAQ:VTGN) on November 13, 2026
Vistagen is listed to report fiscal second quarter 2027 results, covering the quarter ended September 30, 2026, before the market opens (BMO) on November 13, 2026. The call time was not found in published coverage. The consensus estimate per the screener snapshot is a loss of USD 0.37 per share, wider than the USD 0.30 loss in the first quarter. Market capitalization per the screener snapshot is USD 8.33 million, which carries nano-cap risk; the implied price of about USD 0.19 per share, calculated from 44.38 million shares, is unusual and is flagged.
The Rationale: Last Reported Quarter and Management Outlook for Vistagen Therapeutics, Inc. (NASDAQ:VTGN)
For the quarter ended June 30, 2026, Revenue was USD 1.48 million versus USD 244 thousand, mainly USD 1.2 million recognized after the Fuji Pharma exclusivity period expired. Research and Development was USD 10.9 million versus USD 11.7 million, general and administrative was USD 3.9 million versus USD 4.4 million, and operating loss was USD 13.3 million. No numeric guidance was found. Management expects R&D to keep falling depending on FDA feedback, G&A to stay level after a March 2026 reduction in force, and FDA engagement on a registration-directed path for fasedienol in social anxiety disorder.
Valuation, Liquidity and Risks for Vistagen Therapeutics, Inc. (NASDAQ:VTGN)
Per the screener snapshot, Market Value is USD 8.33 million. At June 30, 2026, cash and equivalents were USD 16.99 million, marketable securities were USD 14.74 million, stockholders' Equity was USD 24.48 million and the accumulated Deficit was USD 490.35 million. Cash is expected to fund operations into 2027, but not for more than a year, which raises financing and dilution risk. The PALISADE-4 trial missed its primary endpoint in the overall population, and a post-hoc subgroup result is exploratory. Nano-cap clinical-stage stocks can be Illiquid and volatile.
Where Things Stand
Where things stand: Vistagen Therapeutics, Inc. (NASDAQ:VTGN) reports fiscal second quarter 2027 results before the market opens on November 13, 2026, with a consensus EPS estimate of -0.37 and a market value of USD 8.33 million per the screener snapshot. The prior quarter showed a net loss of USD 13.0 million and total cash and securities of USD 31.7 million, a runway the company limits to roughly into 2027. The central catalyst is the path forward for fasedienol after PALISADE-4, including FDA feedback, alongside the refisolone study clearance. This article is informational and is not Investment advice.


_11_20_2026_14_55_23_118425.jpg)



Please wait processing your request...